Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00145353
Recruitment Status : Unknown
Verified October 2006 by Odense University Hospital. Recruitment status was: Active, not recruiting
The main purpose of the study is to investigate the reason for the reduced number of hypoglycaemic attacks in type 1 diabetic patients when, for a period of time, using Insulin Aspart at meals together with NPH insulin mornings and evenings, and when, in another period of time, using human fast-working insulin at meals and NPH insulin mornings and evenings, and when the patients in both periods simultaneously take extra insulin at meals if high blood glucose values are found before meals.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Type 1 diabetes mellitus treated with insulin four times daily (basal bolus treatment) at least three months before screening.
AGe: 18-60 years
No nefro- or neuropathy; i.e. S-creatinin below 120 μmol/l and normal monofilament examination
Written informed consent
Pregnant women or patients planning to become pregnant during the investigation period
Reduced eyesight; i.e. visus > 0.3 evaluated at the latest eye exam.
Patient lacking the ability to sens insulin sensitivity
Serious rival disease, i.e. heart disease, severe liver or lung impairment, severe psychiatric disease.